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Abstract. Diffuse optical tomography has demonstrated significant potential for clinical utility in the diagnosis
and prognosis of breast cancer, and its use in combination with other structural imaging modalities improves
lesion localization and the quantification of functional tissue properties. Here, we introduce a hybrid diffuse
optical imaging system that operates concurrently with magnetic resonance imaging (MRI) in the imaging
suite, utilizing commercially available MR surface coils. The instrument acquires both continuous-wave and
time-domain diffuse optical data in the parallel-plate geometry, permitting both absolute assignment of tissue
optical properties and three-dimensional tomography; moreover, the instrument is designed to incorporate
diffuse correlation spectroscopic measurements for probing tissue blood flow. The instrument is described in
detail here. Image reconstructions of a tissue phantom are presented as an initial indicator of the system’s
ability to accurately reconstruct optical properties and the concrete benefits of the spatial constraints provided
by concurrent MRI. Last, we briefly discuss how various data combinations that the instrument could facilitate,
including tissue perfusion, can enable more comprehensive assessment of lesion physiology. © The Authors.
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1 Introduction
Diffuse optical tomography (DOT) is a near-infrared optical im-
aging technique that provides three-dimensional (3-D) maps of
tissue optical and physiological properties in human tissue.1–5
The ability of DOT to probe functional tissue parameters non-
invasively is particularly attractive for breast cancer imaging,6
but the technique faces challenges as well. First, DOT image
reconstruction must solve an ill-posed inverse problem;3 second,
DOT spatial resolution is low due to the diffusive nature of
photon transport in tissue.4 Importantly, both limitations can
be ameliorated by utilizing information from another structural
imaging clinical diagnostic. The additional structural informa-
tion can constrain the DOT reconstruction algorithm and thereby
improve assignment of functional tissue properties based on
optical spectroscopy. It also offers the possibility of synthesizing
composite functional parameters based on DOT and the struc-
tural modality, e.g., MRI, X-ray, or ultrasound, that could pro-
vide improved diagnosis or prognosis. Thus, there has been a
significant effort in the optical community to develop instrumen-
tation that can be combined with other, more standard, clinical
imaging modalities.
Indeed, the portable nature, comparatively low cost, and lack
of ionizing radiation associated with diffuse optics makes the
combination with standard clinical modalities relatively simple
compared to the combination of two traditional, stand-alone
clinical imaging modalities, such as MRI-PET. To date, several
groups have successfully combined DOTwith X-ray mammog-
raphy,7–11 ultrasound,12–15 or MRI.16–24 These groups have dem-
onstrated the clear utility of multimodality DOT instruments.
Combining the different imaging modalities into composite
instrumentation is arguably the best approach because data from
the same coregistered volume can be acquired concurrently.
For breast cancer, concurrent imaging is particularly valuable
because the compressibility of breast tissue makes coregistration
with nonconcurrent data difficult, requiring sophisticated defor-
mation algorithms and assumptions.25
To this end, we introduce a hybrid diffuse optical imaging
system that operates concurrently with state-of-the-art clinical
MRI surface coils in the imaging suite. The instrument acquires
both continuous-wave (CW) and time-domain (TD) diffuse opti-
cal data in the parallel-plate geometry, permitting both absolute
assignment of tissue optical properties and rapid 3-D DOT.
The design in the parallel-plate geometry facilitates combining
of a sophisticated research-level optical system with standard
clinical MRI coils; the latter, in turn, enables improved patient
throughput and use of sophisticated and robust MR pulse
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sequences. Moreover, the instrument can incorporate diffuse
correlation spectroscopic measurements (20 source and 20
detector positions) that utilize temporal fluctuations of multiply
scattered light intensity to probe tissue blood flow.4,26,27 In total,
the design thus offers arguably the most versatile and spatially
dense optical dataset reported to date for joint optical-MR
imaging systems.
At this stage, the joint DOT-MRI instrument has been
deployed in the clinic at the Hospital of the University of
Pennsylvania. We have begun to measure healthy volunteers
to test the patient interface and data acquisition algorithms.
The primary purpose of this contribution is to describe the
instrumentation in detail and to present an experimental evalu-
ation of its operation and capabilities. Specifically, image recon-
structions of a tissue phantom are presented, which demonstrate
accurate reconstruction of optical properties and the concrete
benefits of spatial constraints provided by the concurrent MRI.
We will also briefly discuss how various data combinations
that the instrument could facilitate, including tissue perfusion
measured by DCS28–33 or DCE-MRI,34–36 can enable more com-
prehensive assessment of lesion physiology and biomarkers.
2 Instrument Design
This instrument integrates both TD and CW diffuse optical plat-
forms for DOT with either 1.5T or 3T MRI. Adjustable optical
modules permit optimized optode positioning for each subject
and enable optoelectronic compatibility with both standard
clinical systems and future 7T MRI research platforms. As
noted previously, this instrument offers the largest in-magnet,
i.e., concurrently measured with MRI, DOT spatial data sets
reported to date. Acquiring large datasets is particularly difficult
in-magnet due to the requirement of a large number of long
(∼10 m) optical fibers. Figure 1 displays a schematic of the
optical and electronic instrumentation in the system, and
Fig. 2 displays the optoelectronic instrument rack. We will
elaborate in detail on various components below.
2.1 Continuous-Wave Optoelectronic System
The CW measurements are performed using five steady-state
AlGaAs lasers with wavelengths 670 nm (Sony, Tokyo, Japan),
785 nm (Frankfurt Laser Company, Friedrichsdorf, Germany),
808 nm, 850 nm, and 915 nm (Roithner LaserTechnik—Vienna,
Austria). The typical output power of the laser sources at the
tissue interface is between 10 and 27 mW. These lasers feed
five of the inputs to a 12 × 1 optical switch (PiezoJena, Jena,
Germany), the output of which is coupled to a 95∶5 optical
fiber splitter (OZ Optics—Carp, Ontario, Canada). The 95% out-
put of the splitter is then fiber-coupled to an attenuator, which is
coupled to a 1 × 2 optical switch (DiCon FiberOptics, Richmond,
California), and then further to two 1 × 32 optical switches
(DiCon FiberOptics). For CW laser sources, the attenuator is
set to maximize signal delivered to the tissue. The source fibers
are housed in 10-m long, flat 48-strand optical cables (Molex,
Inc., Lisle, Illinois). The proximal ends are broken out into
FC connectors, which attach to the 64 source switch outputs.
The distal ends are coupled via an MTP connector and broken
out into fibers, which are inserted into the optical modules
discussed in Sec. 2.3.
CW detection is performed using 108 1-mm diameter optical
fibers (FiberOptic Systems, Inc., Simi Valley, California), whose
proximal ends are mounted to an imaging plate and imaged onto
an Andor IKon CCD (Model No.: DW936N-#BV—Belfast,
Northern Ireland, United Kingdom). The 5% output from the
fiber splitter coupled to the 12 × 1 switch is also mounted onto
this imaging plate. This fiber serves as a reference channel by
which fluctuations in the laser amplitude are directly measured
and are thus accounted for via normalization of the detected
signal.
Fig. 1 Schematic of DOT-MRI instrument optics and electronics. This hybrid CW and TD DOT-MRI sys-
tem employs six short-pulse (<70 ps) laser sources (690, 750, 780, 798, 838, and 905 nm) for TD meas-
urement of absolute bulk optical properties (absorption and scattering) and five CW laser sources (670,
785, 808, 850, and 915 nm) for producing 3-D reconstructions of relative optical properties. The sources
are coupled to optical imaging modules via a 12 × 1 wavelength switch and an effective 1 × 64 source
position switch, i.e., a 1 × 2 switch and two 1 × 32 switches. A 95∶5 splitter is also used, with the 95% arm
coupled to the source position switch and the 5% arm coupled to a reference channel. CW detection is
performed via detection fibers (108 positions) mounted on a plate and imaged onto a CCD, and TD detec-
tion (8 positions) is accomplished with PMTs and TCSPC modules. All components are controlled via
the instrument computer, digital input/output channels, and a National Instruments DAQ board.
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2.2 Time-Domain Optoelectronic System
The TD system consists of six pulsed laser sources (PicoQuant,
Berlin, Germany) with wavelengths 690, 750, 780, 798, 838,
and 905 nm, coupled to a laser diode driver oscillator (Sepia-II,
PicoQuant). These sources feed six of the remaining channels of
the 12 × 1 wavelength switch (PiezoJena), i.e., channels that are
not occupied by the continuous wave sources. These lasers
deliver ∼30 μW average power to the tissue.
TD light is collected by eight 3-mm optical fibers, which are
each coupled to a photomultiplier tube (PMT, H7422-50mod,
Hamamatsu, Japan). The larger fiber diameter enables more
photons to be collected and thus provides a vital improvement
in signal-to-noise for the PMT detection system. The instrument
contains 16 distinct PMT modules, enabling potential future
expansion. When in use, these PMTs are protected from
saturation by a source-side attenuator, which can adjust for
variation in optical attenuation between subjects. When not in
use, individual computer-controlled shutters protect the detec-
tors. The PMTs are connected to two independent Becker &
Hickl (Berlin, Germany) time-correlated single-photon counting
(TCSPC) modules (SPC-130). Single-photon counting tech-
niques are necessary to temporally resolve the detected signal
collected by the PMTs. Thus, the point-spread functions neces-
sary for the determination of optical properties via TD tech-
niques can be measured.
2.3 Optical Modules, RF Coil, and Imaging Platform
All fibers, including the source fibers, the CCD-coupled CW
detection fibers, and the PMT-coupled TD detection fibers
are gathered together into ∼10-m long mechanically shielded
fiber bundles. The bundles need to be 10 m in length to enable
optical data to be collected inside an MR suite; the instrument’s
electronic modules are not designed to operate in high magnetic
fields and must be kept sufficiently far away, i.e., outside the
restricted area of high magnetic field. The proximal ends of
all fibers are permanently mounted inside four custom-built
optical modules made of gray PVC material with a 3-D printed
plastic shield on the nontissue side to protect the optical fibers.
These materials were demonstrated to have no detectable mag-
netic susceptibility that could contaminate the MR signal. Each
of the four module faces, which are placed in contact with the
tissue, has a length of 16.4 cm and a height of either 3 or 3.5 cm.
This provides a sufficient coverage area of source and detector
positions for most breasts. The two source modules each contain
32 source fibers. The first detector module contains 54 CW
detection fibers and 5 TD detection fibers while the second
detector module contains 54 CW detection fibers but only 3 TD
detection fibers. The fiber optic modules also contain 20 DCS
source fibers, shared across the two detector modules, and 20
single-mode DCS detector fibers (Molex, Inc.), spread across
the two source modules. Note that these fibers are not coupled
to DCS source and detector instrumentation on the current opto-
electronics rack; however, a DCS laser source and detection
hardware, i.e., avalanche photodiodes, have been integrated
in previous work31 and could easily be incorporated into the sys-
tem in the future. Figure 3 contains photographs of the mounted
fibers and the tissue interfaces of the optical modules.
These modules are mounted in a parallel-plate geometry
within the windows of two clinically standard Sentinelle
RF biopsy coils (INVIVO Corp. Gainesville, FL Part
No.:4000044-11). The two source modules are located on the
medial side of the subject’s breast, and the two detector
modules are placed on the lateral side of the breast (see
Fig. 3). This alignment puts the source positions farther away
from the lateral side of the breast, where a majority of breast
tumors form,37 and thus limits contamination between the tumor
contrast and the known imaging artifacts found near the source
plane.38,39 In clinical use, the RF coils have open windows
with plastic grids so that MRI-guided breast biopsies can be
performed. If the plastic grids are removed, the coil provides
a window for the optical modules to couple to tissue.
Importantly, the addition of these optical modules does not
Fig. 2 DOT-MRI system in the clinical MR suite. The optical and electronic components of the DOT-MRI
instrument are housed in an instrument rack on pneumatic wheels for easy transport to and from the MR
suite. The rack contains all laser sources, the pulsed laser diode driver, all optical switches, the CW
detection fiber imaging plate and CCD, PMTs and PMT control-units for TD detection, and TCSPC con-
trol instrumentation. When in use, the DOT instrument rack is brought to the control room of the MR suite
at the Hospital of the University of Pennsylvania. The fiber bundles then pass into the MRI bore and are
incorporated into the clinical breast biopsy RF coil, on which the subject can lie in a prone position to be
simultaneously imaged by MRI and DOT.
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require reconfiguration or modification of the clinical imaging
system. The biopsy coils are housed in a patient imaging plat-
form in which the patient lies prone, and the breast is inserted
between the two coils for simultaneous optical and MR imaging.
The compatible coils available at the Hospital of the University
of Pennsylvania can be used in either 1.5T or 3T large-bore,
clinical MR scanners, e.g., the 1.5T Siemens Espree system
(Erlangen, Germany) currently used for clinical breast imaging
at the Hospital of the University of Pennsylvania. Finally,
MRI fiducial markers are mounted on the optical modules to
permit coregistration of the DOT and MR imaging geometries.
One key advantage of this instrument is the modularity of the
optics at the tissue interface. The number and position of optical
modules within the biopsy window can be easily modified,
enabling optimization of the source and detector locations.
This capability provides better coverage of the tumor region
and limits the number of sources and detectors that are not
directly in contact with tissue due to the curvature of the breast.
In conjunction with the instrument control software, the number
of acquired source–detector pairs can also be chosen to optimize
spatial resolution (many source–detector pairs) or temporal
resolution (few source–detector pairs).
2.4 System Control and Stability
All of the aforementioned optical and electrical components,
along with the instrument control computer, are housed in
a rack-mounted instrument with pneumatic wheels for simple,
safe transport of the instrument to and from the MR suite.
As previously mentioned, the ∼10-m fiber bundles can then
be passed into the MR suite. In this way, the optical modules
can be mounted on the RF coil while the instrument rack
remains outside the high magnetic field of the MRI (see Fig. 2).
The instrument computer controls the function of all compo-
nents through LabVIEW (National Instruments, Austin, Texas)
and Becker & Hickl (Berlin, Germany) software; it is coupled to
the optoelectronic components via digital input/output channels,
a measurement computing board, and a National Instruments
DAQ board (Austin, Texas).
Prior to imaging, the lasers must be turned on for a 30-min
warm-up period. After warmup, the CW laser intensities are
stable to <1%; the remaining power variation is normalized
using the directly measured intensity in the low power arm of
the 95∶5 splitter. The TD system requires a somewhat longer
period of ∼1 h to stabilize.
Light leakage at the detectors is minimized to the point that
DOT images can be successfully carried out in typical clinical
lighting conditions. However, the bore light in the MRI is turned
off, and the subject is covered with a sheet to minimize stray
light at the patient interface. Additionally, absorbing foam
cut-outs are placed underneath the breast to prevent light from
passing directly from source fibers to detectors outside the tissue
and to reduce artifacts due to the boundary between diffusive
and nondiffusive regions.
3 Data Acquisition and Analysis
When using the instrument, three imaging sequences must be
performed for each subject or phantom measurement: CW-
DOT, TD-DOS, and MRI (see Fig. 4). Because the optical
measurements do not interfere with the magnetic field, the
MRI and optical sequences can be performed simultaneously;
however, the CW and TD diffuse optical imaging must be
performed sequentially. In addition to the target measurement,
a reference phantom is imaged using the same TD and CW
sequence as the target. This reference measurement enables
difference reconstruction, i.e., measuring the differences in
optical signal between tissue and a phantom, which reduces
error due to coupling coefficients between fibers and tissue.
3.1 MRI Measurements
The MRI pulse sequences performed with this instrument are
the standard clinical gadolinium-contrast (Gd-contrast) uptake
sequences used for breast MR imaging. These sequences typi-
cally consist of a series of T1- and T2-weighted structural image
sequences, a baseline T1-weighted sequence sensitive to the
Gd-contrast agent, and then a series of images with the same
Gd-sensitive sequence to capture the temporal uptake dynamics
of the Gd-contrast agent. These MR images provide the struc-
ture of the breast and a clear subtraction Gd-contrast image
of the tumor location. The MRI will also image the fiducial
markers placed at known positions on the optical modules,
Fig. 3 Optical source and detector modules. (a) Front view of one
detector module (top) and one source module (bottom). On the detec-
tor module, the large fiber tips are the 3-mm fibers coupled to PMTs,
and the smaller tips are either the 1-mm fibers imaged onto the CCD
or DCS source fibers. The fiber tips on the source modules are either
source fibers coupled to the optical position switch or single-mode
DCS detection fibers. (b) A rear view of the source modules in the
breast biopsy coil. (c) Schematic of the optical modules within the
breast biopsy coil windows in a sagittal parallel-plate configuration
on both sides of the breast. Note that the source modules (medial
side) and the detector modules (lateral side) can be moved vertically
within the biopsy window to ensure coverage of the tumor region of
the breast.
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which enables the coregistration of the optical and MRI co-
ordinate systems.
3.2 Time-Domain Optical Measurements
The optical imaging sequence begins with a series of TD mea-
surements. Approximately 4 of the 64 source positions are illu-
minated with each of the 6 available pulsed laser wavelengths.
These measurements are performed sequentially for each
source-wavelength combination, and all eight available PMT
detector locations are active for every measurement. In practice,
fewer than eight detectors will be used for each source position
due to signal limitations caused by differences in source–
detector separations, which can vary from ∼6 cm to ∼12 cm.
The PMTs, in conjunction with the TCSPC electronics (see
Sec. 2.2), then record point-spread functions for each wave-
length/source–detector combination. These point-spread func-
tions are dependent on the absorption and reduced scattering
coefficients of the tissue. The light pulse input to the tissue is
not a true delta function due to the intrinsic duration of the laser
pulse, as well as the broadening of the light pulse that occurs in
the optical switches, attenuators, and fibers. This broadening,
known as the instrument response function (IRF), is of particular
concern with this DOT-MRI instrument due to the requirement
of long (∼10 cm) optical fibers on both the source and detector
sides. Thus, to distinguish the temporal broadening due to
diffusion through tissue from the inherent broadening in the
instrument, the IRF must be measured. With this system, the
IRF can be found by performing TD measurements without
an optically thick diffusive medium, e.g., without a breast or
phantom, between the source and detector planes. Care must
be taken in this step to attenuate the source light to avoid
saturating and/or damaging the PMTs. Once the IRF is known,
it serves as an effective temporal source profile, which can
be convolved with the Green’s function solution for diffuse
light propagation in an infinite slab. To calculate the optimal
absorption and reduced scattering coefficients, the measured
point-spread function is then fit to this convolution of the
IRF and the Green’s function solution using a nonlinear fitting
algorithm, in this case, the MATLAB file exchange function
fminsearchbnd.40 This method is described in detail in previous
publications.16,41
Since only a few source positions are used for the TD mea-
surements, the fitted absorption and reduced scattering coeffi-
cients for each source–detector pair are typically averaged with
all other measurements at the same wavelength, each of which
probe different regions of the breast. Performing TD measure-
ments at more source positions could enable a sort of coarse
imaging of absolute optical properties; however, this benefit
must be balanced by the time it adds to the patient imaging
sequence. With this instrument, TD imaging of this type is not
feasible within the context of typical MR patient time-windows
of less than 1 h.
3.3 Continuous-Wave Optical Imaging
The CW imaging sequence is performed after the completion of
the TD measurements. Each of the 5 CW laser wavelengths and
63 of the available 64 source positions are cycled through
sequentially. One source position is usually left disconnected
to provide a sham measurement, with no source illumination,
for background normalization purposes. A single frame is
acquired by the CCD for each source-wavelength combination.
This frame will contain the outputs from the fiber tips at the
imaging plate. Thus, each detector fiber will be imaged over
an approximate circle containing ∼80 pixels. The detector loca-
tions on the CCD are determined using a mask for the sum over
all measured frames. The signal used for analysis of a single
detector is the sum over all pixels assigned to that detector
fiber for a single camera frame. Each detector measurement
is then ratio-normalized using the relative intensity of the
CCD reference channel to ameliorate signal contamination due
to laser intensity fluctuations. The entire sequence of source and
wavelength combinations is also performed several times to
assess potential motion artifacts or other systematic instabilities.
The data from these multiple passes through the entire sequence
are then averaged for each wavelength-source–detector combi-
nation. In the case of a clear artifact, data are excluded from
the average.
An optical contrast agent, indocyanine green, could also be
utilized to enhance tumor imaging42–44 and track contrast uptake
dynamics. In such cases, temporal resolution would take
precedence over spectral resolution, and thus, the CW imaging
would be performed at only a single wavelength near the peak
absorption of the contrast agent.
Once this data is collected, single-wavelength or multispec-
tral reconstruction is performed. The absolute bulk absorption
and reduced scattering coefficients from the TD analysis are
used as the initial conditions for the reconstruction. Because
the high-spatial density system is CW, only the absorption coef-
ficient, and by extension, the chromophore concentrations are
reconstructed while the reduced scattering is kept constant.
The knowledge of absolute background absorption coefficient
from the TD instrumentation transforms the relative absorption
coefficients typically reconstructed in CW DOT to absolute
values. In principle, multispectral reconstruction, using a Mie-
like scattering framework and incorporating the TD-measured
reduced scattering, could also be used to reconstruct the reduced
scattering coefficient.
For image reconstruction, we employ a finite-difference
reconstruction method performed using TOAST++.45 This
methodology is a nonlinear, iterative approach, which assumes
a small perturbation between the optical properties of the breast
Fig. 4 DOT-MRI imaging sequence flow chart. The DOT-MRI instru-
ment performs the optical and MRI measurements simultaneously.
Structural T1- and T2-weighted MRI measurements are made prior
to the injection of a gadolinium contrast agent. After the contrast injec-
tion, another set of MR images are acquired, thereby permitting sub-
traction imaging that enables optimal tumor contrast. Simultaneously,
optical data are acquired. First, TD measurements are made at
several positions to determine absolute bulk optical properties. Then,
CW measurements are made at all source and detector positions to
enable full 3-D reconstruction.
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tissue and a reference phantom and utilizes the ratio of the
intensity between the tissue and phantom measurements as the
signal in order to normalize for the source–detector coupling
coefficients. In the phantom reconstructions presented here,
single-wavelength reconstructions are performed. However,
for future human subject data, multispectral reconstruction
algorithms that directly determine the oxy- and deoxyhemo-
globin concentrations could be utilized. Given the substantial
number and range of available wavelengths, water and/or lipid
concentrations could also be reconstructed in those cases. This
task would likely be made easier if a hard-prior constraint were
used (see Sec. 3.4), thereby minimizing the under-determined
nature of the DOT inverse problem.
3.4 Incorporation of MRI Data into DOT
Reconstructions
The primary purpose of simultaneous DOT and MRI, other
than cross-validation, is to exploit the MRI structural images
as a prior constraint for the DOT reconstruction. To this end,
after coregistration of the two co-ordinate systems using the MR
fiducial markers, the MR images must be segmented into dis-
tinct regions. A simple mask for this purpose is created via sig-
nal thresholding, in which signal cutoff values between various
regions are determined, enabling the creation of a four-region
mask, e.g., nontissue, adipose, fibroglandular, and tumor using
either the T1- or T2-weighted MR images. Here, for simplicity,
the MR images were segmented into nontissue, background
breast tissue, and tumor regions using the contrast-enhanced
MRI subtraction image, which provides distinct contrast
between the tumor and the rest of the breast tissue. Figure 5
contains an example of a phantom MRI and the segmented
regions. Note that the regions outside the breast are not recon-
structed from the optical measurements.
Once the MRI has been segmented into distinct regions,
these regions can be used to constrain the DOT reconstruction.
One can utilize the MRI as either a hard prior or a soft prior
for the DOT reconstruction.
A hard-prior constraint uses the segmented image to
define distinct spatial regions and then forces the reconstructed
optical properties to be homogeneous within each region. This
very substantially reduces the number of parameters that must
be reconstructed. Hard-prior constraints have been shown
to improve quantitative contrast between tumor and normal
regions.46–48 However, this technique is very sensitive to system-
atic inaccuracies in the location of the defined regions.49,50
Therefore, accurate segmentation and spatial coregistration
between modalities is imperative.
Another implementation of the segmented image is as a soft
boundary prior, in which the regularization hyperparameter
is lower near region boundaries than in the region interior.
This enforces a smoothing condition within a given region
while allowing for significant updates at the boundaries, where
there is more potential for a physiological nonlinearity.
Soft-prior regularization has been shown to improve optical con-
trast relative to unconstrained DOT39,51–53 but is generally not as
effective in this regard as hard-prior constraints.54,55 It also does
not reduce the parameter space for the inverse problem since all
voxels are still reconstructed. However, soft-prior regularization
does have the advantage of being less critically dependent on
accurate segmentation.
4 Tissue Phantom Imaging Tests
Initial evaluation of the imaging capabilities of the joint
DOT-MRI instrumentation was conducted using a tissue-like
phantom with both magnetic and optical absorption contrast.
This phantom provided a test for the DOT acquisition sequence,
data processing, and image reconstruction techniques in a con-
trolled environment with known optical properties.
4.1 Phantom Construction and Characteristics
Most diffuse optics phantom experiments utilize liquid phan-
toms composed of water, ink for absorption contrast, and
Intralipid for scattering contrast. This approach is not an ideal
solution for experiments performed in the MR suite because
liquid phantoms expose expensive MRI equipment to potential
damaging spills. Thus, a custom gelatin phantom was created
for this investigation.
First, a mold was designed and 3-D printed using a seg-
mented MR image to mimic the approximate shape of a
breast. A porcine gelatin powder (Sigma-Aldrich, St. Louis,
Missouri) was mixed with water, India Ink (Higgins, Leeds,
Massachusetts), a 20% Intralipid soy emulsion (Fresenius Kabi
Global, Bad Homburg, Germany), and a Gd-chelate magnetic
contrast agent (MultiHance—Bracco Diagnostics, Milan, Italy).
To prevent nondiffusive regions from forming in the phantom,
air bubbles were removed from the gelatin mixture using
a vacuum pump prior to the gelatin setting. A hollow target,
16 mm in diameter with 1-mm thick polyoxymethylene walls56
was suspended approximately in the center of the gelatin mold
prior to the pouring of the gelatin. This target was secured
with thin white threads and connected to thin nylon tubing
with both ends of the tubing terminating outside of the gelatin
phantom (see Fig. 5); this set-up enabled injection of small
amounts of liquid with different magnetic and absorption
Fig. 5 Gelatin phantom and mold. (a) One half of the breast-shaped
gelatin phantom mold with target, prior to pouring of the gelatin mix-
ture. The target is held in place by thin, white string which does not
significantly change the optical properties of the phantom. (b) Final
gelatin phantom. Different liquid phantom materials can be injected,
via the nylon tubing, into the target within the gelatin. (c) T1-weighted
MR image of the phantom. (d) Signal-threshold segmentation of
MR image to define distinct regions in the tissue phantom. Here,
the image is segmented into a three region-types, i.e., the liquid target,
the gelatin phantom, and the background region. A three-region
segmented image mask is then ready for use as a hard- or soft-prior
constraint for DOT.
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properties into the target to create varying levels of contrast
with respect to the background phantom.
In this experiment, the background gelatin phantom, which
consisted of gelatin, Gd, ink, and Intralipid, had optical prop-
erties of μa ¼ 0.05 cm−1 and μ 0s ¼ 8 cm−1 at 785 nm. The
concentration of India ink in the target solution was adjusted
to provide 4:1 optical contrast in μa at 785 nm. Phantom
optical properties at other wavelengths can be found in Fig. 7.
The background phantom also contained 0.5 mM MultiHance
Gd-chelate to create an MR contrast relative to the target,
which did not contain the Gd-contrast agent. A reference
phantom was also created for the difference measurements by
injecting a liquid phantom with the same optical and magnetic
properties as the gelatin into the target.
4.2 MR and Optical Imaging
A T1-weighted fat-suppressed gradient echo MRI pulse
sequence was run to derive MR images with good contrast
between the target and background phantom [see Fig. 6(a)].
Optical data were collected using both the CW and TD meas-
urement systems. A single wavelength reconstruction of the
785 nm data is presented here. Note that the absolute optical
properties measured at 780 nm with the TD system were
assumed to be the same as the optical properties at 785 nm
because the India ink has a weak wavelength-dependence in
this spectral regime. Here, the fitted TD data gave absolute
bulk optical properties of μa ¼ 0.053 cm−1 and μ 0s ¼ 7.6 cm−1,
which are within 6% and 5%, respectively, of the background
values we anticipated in constructing the tissue phantom.
The DOT images were reconstructed using the TOAST++
software suite.45 A Gauss–Newton method for the optical prop-
erty update and total variation regularization were used for the
unconstrained reconstruction.57 Figure 6(b) shows this uncon-
strained DOT image, which was created with no a priori infor-
mation from the MRI. Note that this reconstruction provides
relatively good quantitative contrast between the target and
background (see Table 1); however, image artifacts of compa-
rable contrast also arise near the tissue phantom boundary and
near the source and detector planes.
A priori information from the segmented MRI was used to
ameliorate the artifacts and improve contrast. In one case,
a hard-prior constraint from MRI was placed on the DOT
reconstruction, enforcing homogeneous optical property updates
within both the target and background regions [see Fig. 6(c)].
Though this technique eliminates the artifacts, the contrast
between the target and background is unexpectedly low. This
is likely due to an inaccuracy in the co-ordinate system coregis-
tration and thus imperfect spatial designations for the two
regions. To overcome this flaw, soft-prior constraint based on
MRI was also utilized. Here, a first-order Tikhonov regulariza-
tion scheme was used with a regularization parameter that
increased with increasing distance away from the background-
target boundary, which smooths the reconstructed parameters
at locations away from the known discontinuity between the
Fig. 6 Unconstrained, hard-prior, and soft-prior DOT reconstructions.
(a) Sagittal slices, separated by 1 cm, of a T1-weighted fat-sup-
pressed gradient echo MRI of the gelatin phantom and target. Note
that the horizontal lines on the first (source-side) and last (detector-
side) slices are indentations in the phantom from the optical modules.
(b) Sagittal slices of an unconstrained DOT reconstruction. The DOT
reconstruction accurately localizes the target and provides good
absorption contrast relative to the background. However, numerous
boundary artifacts also arise with reconstructed μa values similar to
the targets. (c) Sagittal slices of a DOT reconstruction constrained by
a hard spatial prior. Interestingly, although the artifacts are removed
by the hard-prior constraint, the contrast here is also reduced. This
effect could be due to slight inaccuracies in the co-registration of
the segmented MR image. (d) Sagittal slices of a DOT reconstruction
constrained by a soft spatial prior. Notice that the contrast is slightly
improved and the artifacts are significantly reduced relative to the
unconstrained reconstruction.
Table 1 DOT-MRI reconstructed optical properties. Expected and
reconstructed μa for the spatially unconstrained, hard-prior, and
soft-prior DOT reconstructions in both the background and target
regions, as well as the bulk absolute optical property measurement
by the TD system. Note that the reconstructed contrast is unlikely
to ever fully reach the expected 4∶1 value, which represents the
ratio of target to background μa, due to the broadening of the recon-
structed target. Thus, unconstrained and soft-prior reconstructions
both demonstrate reasonably good contrast.
μa at785 nm ðcm−1Þ
Average background Maximum target Contrast
Expected 0.05 0.20 4∶1
TD 0.053 — —
Unconstrained 0.06 0.14 2.3∶1
Hard-prior 0.051 0.095 1.9∶1
Soft-prior 0.055 0.15 2.7∶1
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background and the target. Figure 6(d) displays this soft-prior
reconstruction. The boundary artifacts present in the uncon-
strained reconstruction are now eliminated, and the contrast
between the target and background has slightly increased.
The soft-prior technique was also used to reconstruct the absorp-
tion coefficient at all CW wavelengths, except for 915 nm.
The very high water content of the phantom led to increased
attenuation of light with wavelengths longer than 900 nm,
which prevented reconstruction with significant target-to-back-
ground contrast. However, the other wavelengths all provided
reasonable contrast (Fig. 7).
5 Discussion
5.1 DOT Reconstruction Validation
The images reconstructed from a breast-shaped, gelatin phan-
tom discussed in Sec. 4.2 provide a validation of the ability
of the DOT-MRI platform to provide high spatial resolution,
3-D images of the absorption coefficient and demonstrate the
utility of using MR images as spatial priors. First, the TD
system produced accurate quantification of the average absolute
absorption and reduced scattering coefficients with errors of
only 6% and 5%, respectively, at 780 nm and similar accuracy
for all other wavelengths. Moreover, the unconstrained CW
reconstruction (see Fig. 6), which was performed with no
input from the MR image, reconstructed the target with reason-
ably good contrast (2.3∶1 versus an expected contrast of 4∶1 at
785 nm) at the appropriate location in three dimensions. Note
that reconstructed images are expected to have lower maximum
contrast than the actual physical contrast due to the partial vol-
ume effect and spatial broadening of the target, which spreads
the total contrast over a larger volume.39,58 Thus, this image
offers evidence that the high-spatial density DOT system
provides quality reconstructions without a priori information.
Despite the quality of the localization, however, there were
artifacts in the absorption reconstruction near the boundaries,
a common issue with DOT reconstructions.59,60
To address these artifacts, a priori structural information from
the MRI was used. A hard-prior reconstruction, whereby the
background and target regions determined by the segmented
MRI are forced to update homogeneously, unexpectedly pro-
vided worse contrast (1.9∶1 at 785 nm) than the unconstrained
reconstruction. Inaccuracies of the coregistration of the optical
and MRI co-ordinate systems could be the cause of this rela-
tively low contrast. Hard-prior reconstructions are particularly
sensitive to this type of image offset.49,50 To mitigate this source
of error in future measurements, more well-defined fiducial
markers in precisely measured locations have been added to
this instrument. The soft-prior constraint reconstruction pro-
vided the best overall image quality for this phantom, with
the highest target-to-background contrast (2.7∶1) and the elimi-
nation of the boundary artifacts found in the unconstrained
reconstruction.
In future human subject imaging, all three types of
reconstruction (unconstrained, hard-prior, and soft-prior) could
be used. The unconstrained image is most useful for directly
validating DOT as an imaging technology against spatially
coregistered, gold-standard MRIs. While the hard-prior is the
most commonly used constraint in this type of imaging, we
have learned that soft-prior reconstructions offer some distinct
advantages. For example, incorporating information about the
normal tissue heterogeneity has been shown to be beneficial,
both for distinguishing malignant from healthy tissue61 and for
predicting response to chemotherapy.62,63 This information is
accessible from a soft-prior reconstruction but is suppressed
by a hard-prior constraint.
5.2 Instrument Advances and Applications
The primary advances associated with the joint imaging system
are the high-spatial density optical information, absolute back-
ground optical property quantification via the TD system, com-
patibility with a clinical RF coil, the inclusion of DCS fibers
for measurement of blood flow, and modular optics to optimize
data collection. These instrument characteristics help to address
Fig. 7 Absorption coefficient reconstructions. TD-DOS was employed to reconstruct the average abso-
lute background μa. Soft-prior constrained CW-DOT was used to reconstruct both background and target
μa using the reconstructed μ 0s value from the TD analysis. Note, the TD and CW background μa are very
close to the expected values. Clear contrast between the target and background is apparent at all
wavelengths; the reduced contrast relative to the true value is expected to arise because of the spatial
broadening of the reconstructed target. TD measurements at 905 nm and CW data at 915 nm were not
reconstructed here because the higher water content of the phantom attenuated the signal too much at
these wavelengths to produce quality reconstructions.
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some of the most interesting applications of DOT in breast
cancer. Specifically, improved reconstruction quality over
DOT-MRI systems with fewer source and detector positions,
and those with only relative optical property calculation, could
enhance both the localization and quantification of tumor optical
and physiological properties, and allow for the development
of composite optical-MR biomarkers. This could enable
improved differentiation between malignant and healthy tissue
and improved characterization of tumors for prediction of
response to chemotherapy. The spatial information provided
by the MRI will also improve the identification of tumor and
normal tissue regions. The advantages provided by increased
spatial information38,39,64,65 and a priori localization11,47–51 are
well-known and have been previously demonstrated by several
other groups.
The incorporation of the clinical coil, which has been
done previously,66 is also a benefit of this system. Effectively,
it provides a more robust MR interface and a more comfortable
patient experience than a custom-built RF coil, which is more
prevalent in multimodality DOT imaging. Patient comfort is
very important, not only for the increased ability to recruit
study subjects, but also because of the reduction in motion
artifacts associated with a comfortable resting position. The
modular design of the optical interface with the RF coil also
enables optimization of the source and detector locations, indi-
vidually optimizing coverage of each tumor and enabling sub-
jects with unusually positioned tumors to be enrolled in trials.
Additionally, the modularity of the optics enables potential
expansion of the instrument, i.e., the introduction of more
source and detector fibers, to perform concurrent bilateral breast
measurement.
The more robust clinical coil also enables relatively simple
implementation of more advanced DCE-MRI techniques, such
as K-space weighted image contrast, which relies on fast, com-
pressed-sensing pulse sequences and imparts information about
tumor perfusion.34–36 These techniques, along with the 20 DCS
source fibers and 20 DCS detector fibers, provide two methods
of obtaining 3-D maps of blood flow with precise structural
knowledge. This blood flow information could also be com-
bined with tissue oxygen saturation measurements, from DOT,
to explore oxygen metabolism,6,29,33 which represents a rela-
tively new biomarker for exploring cancer physiology.
5.3 Future Improvements
During this instrument’s initial testing phase, it became apparent
that several minor improvements were needed. The first, which
has already been completed, is the incorporation of more precise
fiducial markers to improve the coregistration between the opti-
cal and MRI coordinate systems. The fiducial makers are thin
tubes, three of which are attached to each optical module in
orthogonal orientations to ensure accurate localization in all
three dimensions. A second instrumental shortcoming is the
lack of sensitivity of the PMT detectors to the 905-nm pulsed
laser, which reduces the number of available TD wavelengths
and inhibits the system’s ability to accurately reconstruct
water concentration. This limitation could be ameliorated by
complementing the current PMTs with newer, custom-built
PMT modules67 that are more sensitive to infrared light. The
final significant instrument deficiency was an aspect of the
control software. The system is currently designed to capture
frames from the CCD with a single exposure time across all
wavelengths. Because the various CW lasers have different
powers, and because tissue absorbs some wavelengths more
than others, an optimal exposure time for one wavelength
could result in saturation or low signal for another wavelength.
In the current setup, this flaw can be overcome by manually
changing the exposure time for each wavelength in the series;
however, this is a time-consuming process which cannot
feasibly be done during a patient measurement. Thus, it would
be beneficial to automate this procedure by incorporating an
exposure-time optimization scheme. An algorithm to accom-
plish this goal has been designed and is currently being tested
for the instrument.
6 Conclusion
A joint DOT-MRI platform for simultaneous clinical MRI and
hybrid CW and TD optical imaging has been presented. This
system has 64 source fiber positions, 108 CW detector fiber
positions, and 8 TD detector positions, which represents the
most spatially dense DOT-MRI system developed to date.
Importantly, these optode positions are contained in adjustable
modules that can be coupled to 1.5T or 3T clinical MR suites,
enabling improved patient comfort and the use of more
advanced MR pulse sequences. The instrument also utilizes
five CW and six TD laser sources at wavelengths ranging
from 670 to 915 nm, which enables absolute quantification
of optical properties and tissue chromophore concentrations.
Finally, the optical interfaces also contain 20 DCS source
fibers and 20 single-mode DCS detector fibers for the potential
calculation of 3-D blood flow images.
The DOT reconstruction algorithm has been validated
using a breast-shaped gelatin phantom with a liquid target.
Unconstrained, soft-prior constrained, and hard-prior con-
strained images were produced, which demonstrated the ability
of the system to accurately locate lesions and provide reasonable
levels of target-to-background contrast. The soft-prior con-
strained image, in particular, provided a quality reconstruction
with high contrast and limited artifacts.
This system will be used in the clinic to more accurately
quantify tumor and healthy tissue for diagnosis of malignant
lesions, prediction of response to neoadjuvant chemotherapy,
and exploration of blood flow and oxygen metabolism in breast
cancer. Thus, this system provides an excellent opportunity
to improve the accuracy of diffuse optical measurements and
explore the development of multimodal flow and oxygenation
biomarkers that could illuminate tumor physiology.
Disclosures
D.R.B. and A.G.Y. have pending or granted patents on certain
aspects of technology related to diffuse optical spectroscopy.
Neither author currently receives income from nor holds equity
in a company licensing these patents.
Acknowledgments
Funding for this work was provided by National Institutes of
Health under Grant Nos. R01-EB002109, P41-RR002305,
P41-EB014893, NTROI 1U54CA105480, NHLBI HL007915,
the Thrasher Research Fund, and the Whitaker and Fulbright
programs at the Institute for International Education. The
authors would like to thank Dr. Thomas Connick for his assis-
tance in designing and testing the system in the MRI environ-
ment, Norman Butler for his generous advice for developing
a clinically deployable system, Michael Carman for his assis-
tance in mechanical design, and the MR imaging technicians
Journal of Biomedical Optics 051409-9 May 2019 • Vol. 24(5)
Cochran et al.: Hybrid time-domain and continuous-wave diffuse optical tomography instrument with concurrent, clinical magnetic. . .
Downloaded From: https://www.spiedigitallibrary.org/journals/Journal-of-Biomedical-Optics on 1/28/2019
Terms of Use: https://www.spiedigitallibrary.org/terms-of-use
who accommodated our work amidst their busy clinical
schedule. We also thank Dr. Soren D. Konecky and Dr. Regine
Choe for their assistance in developing patient interfaces and
instrument designs, as well as our research coordinators:
Madeline Winters, Ellen Foster, Alexandra Vandegrift, Sarah
Grundy, and Michelle Wong. This project builds on initial
work done by Dr. Xavier Intes and Dr. Vasilis Ntziachristos;
the authors appreciate their guidance. Finally, we thank
Dr. Britton Chance for his vision and foundational work in
the application of diffuse optics to breast cancer.
References
1. D. R. Leff et al., “Diffuse optical imaging of the healthy and diseased
breast: a systematic review,” Breast Cancer Res. Trans. 108(1), 9–22
(2008).
2. B. J. Tromberg et al., “Assessing the future of diffuse optical imaging
technologies for breast cancer management,” Med. Phys. 35(6), 2443–
2451 (2008).
3. S. R. Arridge and J. C. Schotland, “Optical tomography: forward and
inverse problems,” Inverse Probl. 25(12), 123010 (2009).
4. T. Durduran et al., “Diffuse optics for tissue monitoring and tomogra-
phy,” Rep. Prog. Phys. 73(7), 076701 (2010).
5. D. Grosenick et al., “Review of optical breast imaging and spectros-
copy,” J. Biomed. Opt. 21(9), 091311 (2016).
6. D. R. Busch et al., “Towards non-invasive characterization of
breast cancer and cancer metabolism with diffuse optics,” PET Clin.
8(3345–365) (2013).
7. A. Li et al., “Tomographic optical breast imaging guided by three-
dimensional mammography,” Appl. Opt. 42(25), 5181–5190 (2003).
8. Q. Zhang et al., “Coregistered tomographic x-ray and optical breast
imaging: initial results,” J. Biomed. Opt. 10(2), 024033 (2005).
9. Q. Fang et al., “Combined optical and x-ray tomosynthesis breast
imaging,” Radiology 258(1), 89–97 (2011).
10. K. E. Michaelsen et al., “Calibration and optimization of 3D digital
breast tomosynthesis guided near infrared spectral tomography,”
Biomed. Opt. Express 6(12), 4981–4991 (2015).
11. B. B. Zimmermann et al., “Multimodal breast cancer imaging using
coregistered dynamic diffuse optical tomography and digital breast
tomosynthesis,” J. Biomed. Opt. 22(4), 046008 (2017).
12. Q. Zhu et al., “Imager that combines near-infrared diffusive light and
ultrasound,” Opt. Lett. 24, 1050–1052 (1999).
13. M. J. Holboke et al., “Three-dimensional diffuse optical mammography
with ultrasound localization in a human subject,” J. Biomed. Opt.
5, 237–247 (2000).
14. Q. Zhu et al., “Utilizing optical tomography with ultrasound localization
to image heterogeneous hemoglobin distribution in large breast
cancers,” Neoplasia 7(3), 263–270 (2005).
15. Q. Zhu, S. Tannenbaum, and S. H. Kurtzman, “Optical tomography
with ultrasound localization for breast cancer diagnosis and treatment
monitoring,” Surg. Oncol. Clin. N Am. 16, 307–321 (2007).
16. V. Ntziachristos, X. H. Ma, and B. Chance, “Time-correlated single
photon counting imager for simultaneous magnetic resonance and near-
infrared mammography,” Rev. Sci. Instrum. 69(12), 4221–4233 (1998).
17. V. Ntziachristos et al., “MRI-guided diffuse optical spectroscopy of
malignant and benign breast lesions,” Neoplasia 4, 347–354 (2002).
18. B. Brooksby et al., “Magnetic resonance-guided near-infrared tomog-
raphy of the breast,” Rev. Sci. Instrum. 75, 5262–5270 (2004).
19. D. Hsiang et al., “Coregistration of dynamic contrast enhanced MRI
and broadband diffuse optical spectroscopy for characterizing breast
cancer,” Technol. Cancer Res. Trans. 4(5), 549–558 (2005).
20. X. Zhang, V. Toronov, and A. Webb, “Simultaneous integrated diffuse
optical tomography and functional magnetic resonance imaging of
the human brain,” Opt. Express 13(14), 5513–5521 (2005).
21. C. M. Carpenter et al., “Methodology development for three-dimen-
sional MR-guided near infrared spectroscopy of breast tumors,” Opt.
Express 16(22), 17903–17914 (2008).
22. S. Srinivasan et al., “Imaged guided near-infrared spectroscopy of
breast tissue in vivo using boundary element method,” J. Biomed. Opt.
15(6), 061703 (2010).
23. F. El-Ghussein et al., “Hybrid photomultiplier tube and photodiode
parallel detection array for wideband optical spectroscopy of the breast
guided by magnetic resonance imaging,” J. Biomed. Opt. 19(1), 011010
(2014).
24. Y. Zhao et al., “Optimization of image reconstruction for magnetic
resonance imaging-guided near-infrared diffuse optical spectroscopy
in breast,” J. Biomed. Opt. 20(5), 056009 (2015).
25. F. S. Azar et al., “Standardized platform for coregistration of noncon-
current diffuse optical and magnetic resonance breast images obtained
in different geometries,” J. Biomed. Opt. 12(5), 051902 (2007).
26. T. Durduran et al., “Diffuse optical measurement of blood flow, blood
oxygenation, and metabolism in a human brain during sensorimotor
cortex activation,” Opt. Lett. 29(15), 1766–8 (2004).
27. D. A. Boas et al., “Establishing the diffuse correlation spectroscopy sig-
nal relationship with blood flow,” Neurophotonics 3(3), 031412 (2016).
28. T. Durduran et al., “Diffuse optical measurement of blood flow in breast
tumors,” Opt. Lett. 30(21), 2915–2917 (2005).
29. C. Zhou et al., “Diffuse optical monitoring of blood flow and oxygena-
tion in human breast cancer during early stages of neoadjuvant chemo-
therapy,” J. Biomed. Opt. 12(5), 051903 (2007).
30. G. Yu, “Near-infrared diffuse correlation spectroscopy in cancer diag-
nosis and therapy monitoring,” J. Biomed. Opt. 17(1), 010901 (2012).
31. D. R. Busch et al., “Blood flow reduction in breast tissue due to mam-
mographic compression,” Acad. Radiol. 21(2), 151–161 (2014).
32. R. Choe et al., “Optically measured microvascular blood flow contrast
of malignant breast tumors,” PLoS One 9(6), e99683 (2014).
33. J. M. Cochran et al., “Longitudinal optical monitoring of blood flow in
breast tumors during neoadjuvant chemotherapy,” Phys. Med. Biol.
62(12), 4637–4653 (2017).
34. H. K. Song and L. Dougherty, “K-space weighted image contrast
(KWIC) for contrast manipulation in projection reconstruction MRI,”
Magn. Reson. Med. 44(6), 825–832 (2000).
35. H. K. Song and L. Dougherty, “Dynamic MRI with projection
reconstruction and KWIC processing for simultaneous high spatial
and temporal resolution,” Magn. Reson. Med. 52(4), 815–824 (2004).
36. L. Dougherty et al., “High frame-rate simultaneous bilateral breast
DCE-MRI,” Magn. Reson. Med. 57(1), 220–225 (2007).
37. S. Rummel et al., “Tumour location within the breast: does tumour site
have prognostic ability?,” Ecancermedicalscience 9, 552 (2015).
38. J. P. Culver et al., “Three-dimensional diffuse optical tomography in the
parallel plane transmission geometry: evaluation of a hybrid frequency
domain/continuous wave clinical system for breast imaging,” Med.
Phys. 30, 235–247 (2003).
39. H. Y. Ban et al., “Heterodyne frequency-domain multispectral diffuse
optical tomography of breast cancer in the parallel-plane transmission
geometry,” Med. Phys. 43(7), 4383–4395 (2016).
40. J. D’Errico, “fminsearchbnd,” Mathworks File Exchange (2012).
41. S. R. Arridge, M. Cope, and D. T. Delpy, “The theoretical basis for the
determination of optical pathlengths in tissue: temporal and frequency
analysis,” Phys. Med. Biol. 37(7), 1531–1560 (1992).
42. V. Ntziachristos et al., “Concurrent MRI and diffuse optical tomography
of breast after indocyanine green enhancement,” Publ. Natl. Acad. Sci.
USA 97, 2767–2772 (2000).
43. A. Corlu et al., “Three-dimensional in vivo fluorescence diffuse optical
tomography of breast cancer in humans,” Opt. Express 15(11), 6696–
6716 (2007).
44. D. R. Busch, “Computer-aided, multi-modal, and compression diffuse
optical studies of breast tissue,” PhD Thesis, University of Pennsylvania
(2011).
45. M. Schweiger and S. Arridge, “The toast++ software suite for forward
and inverse modeling in optical tomography,” J. Biomed. Opt. 19(4),
040801 (2014).
46. B. Brooksby et al., “Combining near-infrared tomography and magnetic
resonance imaging to study in vivo breast tissue: implementation of
a Laplacian-type regularization to incorporate magnetic resonance
structure,” J. Biomed. Opt. 10(5), 051504 (2005).
47. M. A. Mastanduno et al., “MR-guided near-infrared spectral tomogra-
phy increases diagnostic performance of breast MRI,” Clin. Cancer Res.
21(17), 3906–3912 (2015).
48. J. Feng et al., “Multiobjective guided priors improve the accuracy of
near-infrared spectral tomography for breast imaging,” J. Biomed. Opt.
21(9), 090506 (2016).
Journal of Biomedical Optics 051409-10 May 2019 • Vol. 24(5)
Cochran et al.: Hybrid time-domain and continuous-wave diffuse optical tomography instrument with concurrent, clinical magnetic. . .
Downloaded From: https://www.spiedigitallibrary.org/journals/Journal-of-Biomedical-Optics on 1/28/2019
Terms of Use: https://www.spiedigitallibrary.org/terms-of-use
49. G. Boverman et al., “Quantitative spectroscopic diffuse optical tomog-
raphy of the breast guided by imperfect a priori structural information,”
Phys. Med. Biol. 50(17), 3941–3956 (2005).
50. B. Deng et al., “Impact of errors in experimental parameters on recon-
structed breast images using diffuse optical tomography,” Biomed. Opt.
Express 9(3), 1130–1150 (2018).
51. X. Intes et al., “Diffuse optical tomography with physiological and
spatial a priori constraints,” Phys. Med. Biol. 49(12), N155 (2004).
52. M. Guven et al., “Diffuse optical tomography with a priori anatomical
information,” Phys. Med. Biol. 50(12), 2837–2858 (2005).
53. P. K. Yalavarthy et al., “Weight-matrix structured regularization
provides optimal generalized least-squares estimate in diffuse optical
tomography,” Med. Phys. 34(6), 2085–2098 (2007).
54. B. W. Pogue et al., “Implicit and explicit prior information in near-infra-
red spectral imaging: accuracy, quantification and diagnostic value,”
Philos. Trans. A Math. Phys. Eng. Sci. 369(1955), 4531–4557 (2011).
55. L. Wu et al., “Shape-parameterized diffuse optical tomography holds
promise for sensitivity enhancement of fluorescence molecular tomog-
raphy,” Biomed. Opt. Express 5(10), 3640–3659 (2014).
56. R. Ziegler et al., “Nonlinear reconstruction of absorption and fluores-
cence contrast from measured diffuse transmittance and reflectance of a
compressed-breast-simulating phantom,” Appl. Opt. 48(24), 4651–4662
(2009).
57. M. Schweiger, S. R. Arridge, and I. Nissila, “Gauss-Newton method for
image reconstruction in diffuse optical tomography,” Phys. Med. Biol.
50(10), 2365–2386 (2005).
58. M. A. O’Leary, “Imaging with diffuse photon density waves,” PhD
Thesis, University of Pennsylvania (1996).
59. B. W. Pogue et al., “Spatially variant regularization improves diffuse
optical tomography,” Appl. Opt. 38(13), 2950–2961 (1999).
60. R. Choe et al., “Differentiation of benign and malignant breast tumors
by in-vivo three-dimensional parallel-plate diffuse optical tomography,”
J. Biomed. Opt. 14(2), 024020 (2009).
61. D. R. Busch et al., “Computer aided automatic detection of malignant
lesions in diffuse optical mammography,”Med. Phys. 37(4), 1840–1849
(2010).
62. D. R. Busch et al., “Optical malignancy parameters for monitoring
progression of breast cancer neoadjuvant chemotherapy,” Biomed. Opt.
Express 4(1), 105–21 (2013).
63. J. M. Cochran et al., “Tissue oxygen saturation predicts response to
breast cancer neoadjuvant chemotherapy within 10 days of treatment,”
J. Biomed. Opt. 24(2), 021202 (2018).
64. M. L. Flexman et al., “Digital optical tomography system for dynamic
breast imaging,” J. Biomed. Opt. 16, 076014 (2011).
65. V. Krishnaswamy et al., “A digital x-ray tomosynthesis coupled near
infrared spectral tomography system for dual-modality breast imaging,”
Opt. Express 20(17), 19125–36 (2012).
66. M. A. Mastanduno et al., “Adaptable near-infrared spectroscopy fiber
array for improved coupling to different breast sizes during clinical
MR,” Acad. Radiol. 21(2), 141–150 (2014).
67. P. Taroni et al., “Seven-wavelength time-resolved optical mammogra-
phy extending beyond 1000 nm for breast collagen quantification,”
Opt. Express 17(18), 15932–15946 (2009).
Jeffrey M. Cochran is a postdoctoral fellow in the Department
of Physics and Astronomy at the University of Pennsylvania. He
received his BS degree in physics from Denison University and his
PhD in physics from the University of Pennsylvania. His research
is focused on developing noninvasive imaging biomarkers of disease
using diffuse optical techniques.
David R. Busch is an assistant professor in the Department of
Anesthesiology and Pain Management and Department of Neurology
and Neurotherapeutics at the University of Texas Southwestern
Medical Center. His work focuses on developing noninvasive and
minimally invasive optical tools to monitor deep tissues in health
and disease, as well as throughout therapy.
Li Lin is currently a PhD candidate at Caltech under the tutelage of
professor Lihong V. Wang. He earned his master’s degree at the
University of Pennsylvania in 2013 and his bachelor’s degree at
Tianjin University in 2011. His research focuses on photoacoustic
computed tomography and microscopy (PAM), specifically in human
breast and animal brain imaging.
Simon Arridge received his BA degree in natural sciences from
Cambridge University and his PhD in medical physics from University
College London. Currently, he is professor of image processing in
the Department of Computer Science at University College London,
director of the Centre for Inverse Problems, and a member of the
board of directors of the Centre for Medical Image Computing. His
research interests are in inverse problems in imaging, mathematical
modelling, and computational methods.
Arjun G. Yodh is the James M. Skinner professor of science in
the Department of Physics and Astronomy at the University of
Pennsylvania. He directs the Laboratory for Research on the
Structure of Matter, an interdisciplinary materials institute that hosts
the Penn MRSEC. His biomedical research is oriented toward diffuse
optical imaging and monitoring, aiming to demonstrate the potential of
these tools for functional imaging/monitoring in brain, breast, and
muscle.
Biographies of the other authors are not available.
Journal of Biomedical Optics 051409-11 May 2019 • Vol. 24(5)
Cochran et al.: Hybrid time-domain and continuous-wave diffuse optical tomography instrument with concurrent, clinical magnetic. . .
Downloaded From: https://www.spiedigitallibrary.org/journals/Journal-of-Biomedical-Optics on 1/28/2019
Terms of Use: https://www.spiedigitallibrary.org/terms-of-use
